5-Amino-1MQ: NAD+ Boosting Peptide for Metabolism

The connection between NAD+ and metabolic health has become one of the most active areas in longevity and optimization research. NAD+, or nicotinamide adenine dinucleotide, is a coenzyme that is fundamental to cellular energy production, DNA repair, and the activity of sirtuins, a family of proteins linked to longevity and metabolic regulation. As we age, NAD+ levels decline, and this decline is associated with metabolic dysfunction, increased fat accumulation, and reduced cellular energy.

5-Amino-1MQ approaches the NAD+ problem from a different angle than supplements like NMN or NR, which provide raw precursors for NAD+ production. Instead, it blocks the enzyme that degrades NAD+ precursors, effectively closing a drain rather than turning up the faucet. This guide covers how it works, what the research shows, and what you need to consider. We do not provide dosing information. Any use should be under physician supervision.

What is 5-Amino-1MQ?

5-Amino-1MQ, formally known as 5-amino-1-methylquinolinium, is a small molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). While it is commonly discussed in the peptide therapy space and is often available through compounding pharmacies that specialize in peptides, it is technically a small organic molecule rather than a peptide. This distinction is relevant because it means 5-Amino-1MQ can be taken orally, a significant practical advantage over most peptides that require injection due to their degradation in the gastrointestinal tract.

NNMT is an enzyme that methylates nicotinamide, converting it to 1-methylnicotinamide. This reaction consumes S-adenosyl methionine (SAM) as a methyl donor and removes nicotinamide from the NAD+ salvage pathway. In simpler terms, NNMT takes a building block that the body uses to make NAD+ and converts it into a form that can no longer be used for NAD+ production. When NNMT activity is high, it creates a metabolic bottleneck that depletes NAD+ levels and impairs the many cellular processes that depend on this critical coenzyme.

What makes this particularly relevant to metabolic health is that NNMT expression is significantly elevated in obesity and metabolic dysfunction. Research has shown that fat tissue in obese individuals expresses substantially more NNMT than fat tissue in lean individuals. This overexpression creates a vicious cycle: excess NNMT depletes NAD+, which impairs metabolic function, which promotes further fat accumulation, which drives more NNMT expression. Inhibiting NNMT with 5-Amino-1MQ is designed to break this cycle.

The compound was developed through academic research into NNMT biology, and its application in clinical metabolic optimization is relatively recent. While the underlying science of NNMT inhibition is well-characterized, the translation of 5-Amino-1MQ specifically into clinical use is still in its early stages.

How 5-Amino-1MQ works

The mechanism of 5-Amino-1MQ is centered on a single target, NNMT inhibition, but the downstream effects of blocking this enzyme touch multiple metabolic pathways.

NAD+ restoration. By inhibiting NNMT, 5-Amino-1MQ prevents the diversion of nicotinamide away from the NAD+ salvage pathway. This allows more nicotinamide to be recycled into NAD+ through the action of the enzyme NAMPT (nicotinamide phosphoribosyltransferase). The result is increased intracellular NAD+ levels without the need for exogenous NAD+ precursor supplementation. This is a fundamentally different approach from taking NMN or NR supplements, which provide additional precursor molecules. 5-Amino-1MQ instead preserves the precursors the body already has by blocking the enzyme that wastes them.

Sirtuin activation. NAD+ is a required cofactor for sirtuins, a family of seven enzymes (SIRT1-7) that regulate numerous metabolic processes including fat metabolism, inflammation, DNA repair, and cellular stress responses. Sirtuins have been extensively studied in the context of aging and longevity, and their activity is limited by NAD+ availability. By increasing NAD+ levels, 5-Amino-1MQ indirectly supports sirtuin activity. SIRT1, in particular, plays a direct role in fat metabolism by promoting lipolysis and inhibiting adipogenesis (the formation of new fat cells).

SAM/SAH ratio modulation. NNMT consumes SAM (S-adenosyl methionine) as a methyl donor in its reaction. When NNMT activity is high, it depletes SAM and produces SAH (S-adenosyl homocysteine), shifting the SAM/SAH ratio. This ratio is a critical determinant of methylation capacity throughout the body, affecting gene expression, protein function, and numerous metabolic reactions. By reducing NNMT activity, 5-Amino-1MQ helps preserve SAM levels and maintain a healthy SAM/SAH ratio, which has broad implications for cellular function beyond just NAD+ metabolism.

Fat cell metabolism. Research has demonstrated that NNMT inhibition shifts fat cell behavior. In cell culture studies, NNMT knockdown or pharmacological inhibition promotes the expression of genes associated with energy expenditure and reduces the expression of genes associated with fat storage. Essentially, NNMT inhibition nudges fat cells toward a more metabolically active state where they burn energy rather than store it. This effect has been observed in both white adipose tissue and in the browning of white fat cells, where white fat takes on characteristics of metabolically active brown fat.

Muscle preservation. An important characteristic of the metabolic effects of NNMT inhibition is that fat reduction appears to occur without loss of lean muscle mass. In animal studies, NNMT inhibition reduced body fat while preserving or even slightly increasing lean body mass. This selectivity is significant because many weight loss interventions result in loss of both fat and muscle, which can impair metabolic rate and functional capacity. The preservation of lean mass during fat loss is consistent with the NAD+/sirtuin-mediated mechanism, as sirtuins are also involved in maintaining muscle cell function and preventing muscle atrophy.

Research and evidence

NNMT in obesity

The foundational research linking NNMT to metabolic dysfunction is robust. Multiple studies have demonstrated that NNMT expression is elevated in the adipose tissue and liver of obese individuals compared to lean controls. Genetic studies in mice have shown that NNMT knockdown (reducing NNMT expression through genetic manipulation) protects against diet-induced obesity, improves insulin sensitivity, and increases energy expenditure without affecting food intake. These genetic studies provide strong evidence that NNMT activity is causally related to metabolic dysfunction, not merely correlated with it.

Research published in Nature in 2014 demonstrated that NNMT is one of the most differentially expressed genes in white adipose tissue between obese and lean individuals, establishing it as a significant metabolic target. This study also showed that reducing NNMT expression in fat cells increased their metabolic activity and energy expenditure, providing the mechanistic rationale for pharmacological NNMT inhibition.

Pharmacological NNMT inhibition

Studies using NNMT inhibitors, including compounds structurally related to 5-Amino-1MQ, have confirmed the metabolic effects predicted by genetic studies. In diet-induced obesity models, NNMT inhibitor treatment reduced body weight and fat mass, improved glucose tolerance, and increased energy expenditure. These effects occurred without changes in food intake, consistent with a mechanism that increases metabolic rate rather than suppressing appetite.

Cell culture studies have demonstrated that NNMT inhibition increases NAD+ levels, activates AMPK (a key metabolic sensor and regulator), and promotes the expression of uncoupling proteins associated with thermogenesis. These molecular findings provide a coherent mechanistic picture of how blocking NNMT translates to metabolic benefits at the whole-organism level.

Evidence limitations

The primary limitation of the current evidence base is the gap between the strong preclinical data on NNMT inhibition and the limited human clinical data specifically on 5-Amino-1MQ. The NNMT biology is well-established, and the rationale for inhibiting it is scientifically sound. However, large-scale, controlled human clinical trials of 5-Amino-1MQ for metabolic optimization have not been published as of this writing.

Practitioners in the optimization medicine space have accumulated clinical experience with 5-Amino-1MQ, and anecdotal reports generally describe improvements in body composition, energy levels, and metabolic markers. These observations are consistent with the predicted effects of NNMT inhibition but carry the limitations inherent to uncontrolled clinical observation. The compound is early in its clinical lifecycle, and the evidence base will mature as more physicians incorporate it into practice and as formal studies are conducted.

Clinical context

5-Amino-1MQ is typically used in the context of broader metabolic optimization protocols. It is not a standalone weight loss drug but rather a metabolic modifier that physicians use alongside other interventions including nutrition optimization, exercise programming, and sometimes other peptides or metabolic therapies.

The connection between NNMT inhibition and NAD+ restoration places 5-Amino-1MQ at the intersection of two significant areas of optimization medicine: metabolic health and longevity science. For patients who are also interested in NAD+ optimization through other approaches, 5-Amino-1MQ can be considered complementary to, rather than a replacement for, interventions like NAD+ IV therapy or NMN/NR supplementation. The mechanisms are different and potentially synergistic: precursor supplementation provides more raw material for NAD+ production, while NNMT inhibition prevents the wasteful degradation of those same precursors.

The oral bioavailability of 5-Amino-1MQ is a significant practical advantage. Unlike most peptides used in optimization medicine, which require subcutaneous injection, 5-Amino-1MQ can be taken as an oral capsule. This simplifies administration and improves patient compliance, particularly for individuals who are uncomfortable with self-injection or who are using the compound as part of a long-term metabolic optimization strategy.

For patients interested in the broader context of how metabolic optimization fits into longevity and health span strategies, see our guide on longevity supplements. For those specifically focused on body composition, our comprehensive weight loss guide covers the full landscape of evidence-based approaches.

Frequently asked questions

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase). By blocking NNMT, it prevents the degradation of NAD+ precursors, allowing intracellular NAD+ levels to increase. This supports cellular energy metabolism, fat metabolism, and sirtuin activity. While commonly discussed alongside peptides, it is technically a small molecule rather than a peptide, which gives it the advantage of oral bioavailability.

How does 5-Amino-1MQ help with weight loss?

By inhibiting NNMT and increasing NAD+ availability, 5-Amino-1MQ enhances cellular energy metabolism, promotes metabolically active fat cell phenotypes, and supports sirtuin activation. Animal studies show that NNMT inhibition reduces body fat without affecting food intake or lean muscle mass, suggesting a metabolic shift rather than caloric restriction. The compound is typically used as part of a comprehensive metabolic optimization protocol rather than as a standalone weight loss intervention.

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small organic molecule, specifically a quinolinium compound. It is discussed alongside peptides because it is used in similar clinical contexts and is available through compounding pharmacies that specialize in peptide therapy. Its small molecule nature is actually advantageous because it allows oral administration, unlike most peptides which require injection.

What is NNMT and why does it matter?

NNMT is an enzyme that consumes NAD+ precursors, reducing the availability of NAD+ for cellular metabolism. It is overexpressed in obesity, creating a cycle where excess NNMT depletes NAD+, impairs metabolism, and promotes fat accumulation. Inhibiting NNMT breaks this cycle. Research has established NNMT as one of the most significantly overexpressed genes in adipose tissue of obese individuals, making it a validated metabolic target.

Is 5-Amino-1MQ safe?

Animal studies have not reported significant adverse effects from NNMT inhibition, and clinical use has not generated reports of serious adverse events. However, long-term human safety data is limited, and the compound affects fundamental metabolic pathways. Physician supervision is important for monitoring metabolic markers and ensuring appropriate use. Patients should understand that 5-Amino-1MQ is relatively new in clinical practice and the safety profile is still being characterized.